CONTOUR® NEXT LINK 2.4 FROM ASCENSIA DIABETES CARE, THE FIRST PMA-APPROVED BGMS, FEATURED IN U.S. LAUNCH OF MINIMED® 670G HYBRID CLOSED LOOP SYSTEM BY MEDTRONIC
Parsippany, June 6, 2017
Ascensia Diabetes Care today announced the commercial launch by Medtronic of the MiniMed® 670G system in the United States. The MiniMed® 670G system is the first Hybrid Closed Loop (HCL) insulin delivery system to be approved anywhere in the world and exclusively features the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System (BGMS) from Ascensia Diabetes Care.
ASCENSIA DIABETES CARE RECEIVES FDA CLEARANCE FOR THE APP-ENABLED CONTOUR® NEXT ONE BLOOD GLUCOSE MONITORING SYSTEM
Parsippany, November 21, 2016
Ascensia Diabetes Care announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CONTOUR® NEXT ONE Blood Glucose Monitoring System (BGMS), marking a key step in making the next-generation system available to people living with diabetes in the U.S.
ASCENSIA DIABETES CARE LAUNCHES CONTOUR® NEXT LINK 2.4 WIRELESS BLOOD GLUCOSE MONITORING SYSTEM AS PART OF THE MEDTRONIC MINIMED® 630G SYSTEM WITH SMARTGUARD™ TECHNOLOGY
Parsippany, August 11, 2016
Ascensia Diabetes Care has today announced the commercial launch and approval from the U.S. Food and Drug Administration (FDA) of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System (BGMS) as part of the Medtronic MiniMed® 630G system with SmartGuard™ technology.
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million
Leverkusen, June 10, 2015
Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation.